Fin J. Milder
Research Subjects
Research Interests
Fin J. Milder has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Baerbel Kaufmann
Janssen Vaccines & Prevention BV, 2333 CN Leiden, The Netherlands
1 shared publication- Boerries Brandenburg
Janssen Vaccines & Prevention, Leiden, the Netherlands
1 shared publication - Daniel Veldman
Janssen Vaccines & Prevention BV, 2333 CN Leiden, The Netherlands
1 shared publication - Ilona J. M. Bisschop
Janssen Vaccines & Prevention BV, 2333 CN Leiden, The Netherlands
1 shared publication Jarek Juraszek
Janssen Vaccines & Prevention BV, 2333 CN Leiden, The Netherlands
1 shared publication- Johannes P. M. Langedijk
Janssen Vaccines & Prevention BV, Leiden, the Netherlands
1 shared publication
Latest Publications
- Open Access
- 7 February 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (6)
Universal stabilization of the influenza hemagglutinin by structure-based redesign of the pH switch regions
Significance: Influenza hemagglutinin (HA) is a prototypical class I fusion protein and a major component of current flu vaccines. HA is a metastable glycoprotein and undergoes conformational changes to the so-called postfusion state. Stabilization of the prefusion conformations of fusion proteins has proven to be a key success factor for the induction of efficacious immune response and stabilization has become a grand challenge in structural vaccinology. The study shows that three stabilizing mutations in two important pH-sensitive switch regions involved in the early refolding process impede refolding of the prefusion HA. Based on the substitutions of these highly conserved and buried HA residues a generally applicable stabilization strategy for all subtypes of group 1 and 2 influenza A HA was developed.
- 7 February 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (6)
Open AccessUniversal stabilization of the influenza hemagglutinin by structure-based redesign of the pH switch regions
Significance: Influenza hemagglutinin (HA) is a prototypical class I fusion protein and a major component of current flu vaccines. HA is a metastable glycoprotein and undergoes conformational changes to the so-called postfusion state. Stabilization of the prefusion conformations of fusion proteins has proven to be a key success factor for the induction of efficacious immune response and stabilization has become a grand challenge in structural vaccinology. The study shows that three stabilizing mutations in two important pH-sensitive switch regions involved in the early refolding process impede refolding of the prefusion HA. Based on the substitutions of these highly conserved and buried HA residues a generally applicable stabilization strategy for all subtypes of group 1 and 2 influenza A HA was developed.